Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06662890

Heart Attack Blood Oxygen Therapy Trial

Led by NHS National Waiting Times Centre Board · Updated on 2025-02-24

56

Participants Needed

1

Research Sites

731 weeks

Total Duration

On this page

Sponsors

N

NHS National Waiting Times Centre Board

Lead Sponsor

B

British Heart Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

'Heart attack', known as acute ST-segment elevation myocardial infarction, is a leading cause of heart failure and death. A lack of blood and oxygen damages the heart muscle potentially causing heart failure and premature death. During the past 25 years, despite intensive research efforts, few, if any new medicines have been shown to prevent heart failure after a heart attack. New treatment approaches are needed. The standard treatment for a heart attack is for a doctor to reopen the blocked blood vessel. The treatment is called primary percutaneous coronary intervention, or 'primary PCI'. The doctor places a thin plastic tube in a blood vessel in the wrist. The doctor then passes a longer thin tube via the wrist into the blocked heart artery. A small balloon is then used to open the blockage and a thin metal tube (stent) is placed inside the blood vessel to keep it open. The patient then returns to the ward. Supersaturated oxygen therapy is designed to increase the blood oxygen level after the stent has been placed. The treatment lasts for one hour. The treatment is approved (CE-mark, FDA-approved) for patients presenting to doctors within 6 hours of symptoms onset. Supersaturated oxygen therapy is supported by results from two prior studies (AMIHOT, AMIHOT-II). Previously, the approach involved passing the plastic tubes via the femoral artery in the groin, limiting adoption. Since using the wrist is now standard care approach for heart attack treatment, our idea is to give supersaturated oxygen therapy via the wrist rather than the groin. In this research study, we aim to assess the feasibility, safety and potential benefits of increasing blood oxygen content in patients who have been treated for a heart attack. The novel aspects of the study including giving the therapy via the wrist, the dummy procedure (sham/placebo), the randomized treatment assignment (coin-flip, play of chance), and the masking (blinding) of the patient participating in the study and the attending clinical staff, investigators and outcome assessors. Patients who have been successfully treated for a heart attack will be invited to give informed consent at the end of the procedure. Fifty-six patients who have experienced a heart attack affecting the main area of the heart (anterior wall) will receive supersaturated therapy, or a dummy procedure, for one hour. The dummy procedure involves local anesthetic in the wrist and a pressure band as would normally be done. The study also involves measuring small vessel function before and after the supersaturated oxygen / dummy procedure, a heart MRI scan at 2-5 days and again 3 months later, health questionnaires and blood samples to assess heart injury and to be stored for future research. The study will provide information on safety, feasibility and preliminary insights into potential benefits to patients. The study will clarify whether a much larger study is warranted.

CONDITIONS

Official Title

Heart Attack Blood Oxygen Therapy Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Ischemic time 6 hours or less from symptom onset
  • Acute anterior ST-segment elevation myocardial infarction
  • Infarct-related left anterior descending coronary artery TIMI flow grade 2-3 at the end of PCI
  • Radial artery access used during PCI
  • Partial pressure of oxygen (PaO2) greater than 80 mmHg (10.7 kPa)
Not Eligible

You will not qualify if you...

  • Proximal coronary artery narrowing that restricts blood flow with the SSO2 catheter in place
  • Post-PCI non-stented dissection or perforation
  • Moderate to severe heart valve problems, pericardial disease, or non-ischemic cardiomyopathy
  • Known pregnancy
  • Cardiogenic shock
  • Contraindication to anticoagulation
  • Acute mechanical complications such as ventricular septal rupture, pseudoaneurysm, or mitral regurgitation
  • Hemoglobin less than 10 g/dL
  • Major bleeding or major surgery within the past two months
  • Contraindication to cardiovascular magnetic resonance imaging (e.g., severe claustrophobia, metallic foreign body)
  • Lack of witnessed verbal consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Golden Jubilee National Hospital

Clydebank, Dunbartonshire, United Kingdom, G81 4DY

Actively Recruiting

Loading map...

Research Team

C

Colin Berry, BSc MBChB PhD

CONTACT

K

Katherine Henry, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here